Teriparatide has a theoretical risk of [[osteosarcoma]], which was found in rat studies but not confirmed in humans.<ref name="Riek"/> This may be because unlike humans, rat bones grow for their entire life.<ref name="Riek"/> The tumors found in the rat studies were located on the end of the bones which grew after the injections began.<ref name="Ref_a">http://www.drugs.com/pro/forteo.html</ref> After nine years on the market, there were only two cases of osteosarcoma reported.<ref name="Kawai"/> This risk was considered by the FDA as "extremely rare" (1 in 100,000 people)<ref name="Rizzoli"/> and is only slightly more than the incidence in the population over 60 years old (0.4 in 100,000).<ref name="Rizzoli"/>

 

